Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIO NASDAQ:GRTX NASDAQ:JBIO NASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$3.68+1.1%$3.92$3.22▼$53.10$6.42M2.9637,582 shs19,902 shsGRTXGalera Therapeutics$0.02-6.2%$0.03$0.02▼$0.08$1.71M1.9190,335 shs33,850 shsJBIOJade Biosciences$8.23+11.5%$8.70$6.57▼$105.00$240.79M1.03118,290 shs124,711 shsSBFMSunshine Biopharma$1.40-1.4%$1.49$1.17▼$3.90$6.47M1.4544,669 shs18,885 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics+1.10%+1.38%-16.55%-6.84%-72.11%GRTXGalera Therapeutics-6.22%+0.44%-7.76%-7.00%-65.65%JBIOJade Biosciences+11.52%+11.82%-5.51%+822,999,900.00%+822,999,900.00%SBFMSunshine Biopharma-2.17%-6.03%-11.39%-2.78%-53.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDIOCardio Diagnostics2.5743 of 5 stars3.53.00.00.01.71.70.6GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AJBIOJade Biosciences1.7902 of 5 stars3.50.00.00.01.81.70.0SBFMSunshine Biopharma2.1287 of 5 stars3.53.00.00.01.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 3.00Buy$60.001,530.43% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/AJBIOJade Biosciences 3.00Buy$16.0094.41% UpsideSBFMSunshine Biopharma 3.00Buy$15.00971.43% UpsideCurrent Analyst Ratings BreakdownLatest GRTX, SBFM, CDIO, and JBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025JBIOJade BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.007/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$40K161.92N/AN/A$5.52 per share0.67GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$6.18 per shareN/ASBFMSunshine Biopharma$34.87M0.18N/AN/A$5.63 per share0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-30,465.10%-72.78%-66.17%N/AGRTXGalera Therapeutics-$59.08M-$0.19N/A∞N/AN/AN/A-99.34%N/AJBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/ASBFMSunshine Biopharma-$5.13M-$150.88N/A∞N/A-17.35%-26.04%-20.72%11/3/2025 (Estimated)Latest GRTX, SBFM, CDIO, and JBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CDIOCardio Diagnostics-$1.80-$0.97+$0.83-$0.97$0.08 million$0.01 million8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/A8/12/2025Q2 2025SBFMSunshine Biopharma-$0.11-$0.39-$0.28-$0.39$12.10 million$9.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A23.5219.47GRTXGalera TherapeuticsN/A9.749.74JBIOJade BiosciencesN/A10.3110.31SBFMSunshine BiopharmaN/A5.002.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%GRTXGalera Therapeutics50.77%JBIOJade BiosciencesN/ASBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics22.30%GRTXGalera Therapeutics12.90%JBIOJade Biosciences24.90%SBFMSunshine Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics11.76 million1.37 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableJBIOJade Biosciences2032.63 million632,000N/ASBFMSunshine Biopharma34.56 million4.55 millionNot OptionableGRTX, SBFM, CDIO, and JBIO HeadlinesRecent News About These CompaniesSunshine Biopharma Launches NIOPEG (R) Into $10 Billion Biologics Market - MorningstarJuly 3, 2025 | morningstar.comMSBFM - Sunshine Biopharma Inc News - MorningstarJuly 3, 2025 | morningstar.comMSunshine Biopharma, Inc. (SBFM) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comSunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics MarketJuly 2, 2025 | accessnewswire.comASunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’June 11, 2025 | msn.comSunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion MarketJune 11, 2025 | accessnewswire.comASunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last YearMay 15, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | finanznachrichten.deSunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | accessnewswire.comASunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comSunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 BillionApril 21, 2025 | accessnewswire.comASunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct OfferingApril 3, 2025 | accessnewswire.comAThis Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2, 2025 | msn.comSunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesApril 2, 2025 | accessnewswire.comASunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2, 2025 | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2, 2025 | finance.yahoo.comSunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearApril 1, 2025 | accessnewswire.comASunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comSunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in CanadaMarch 24, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTX, SBFM, CDIO, and JBIO Company DescriptionsCardio Diagnostics NASDAQ:CDIO$3.68 +0.04 (+1.10%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$3.67 -0.01 (-0.16%) As of 08/22/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-6.22%) As of 08/22/2025 03:34 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Jade Biosciences NASDAQ:JBIO$8.23 +0.85 (+11.52%) As of 08/22/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Sunshine Biopharma NASDAQ:SBFM$1.40 -0.02 (-1.41%) Closing price 08/22/2025 03:49 PM EasternExtended Trading$1.46 +0.07 (+4.64%) As of 08/22/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access